Meningococcal Vaccines; Highly Effective at Protecting Against Strains of the Meningococcal Bacteria

Meningococcal Vaccines
Meningococcal Vaccines

Meningococcal Vaccines refers to vaccines used to prevent infection by Neisseria meningitidis bacteria. It is a serious bacterial infection that can result in organ damage or death. Thus, early treatment is important and vaccination is a step towards prevention. Controlling epidemics of the disease depends on both antibiotics and vaccination. The U.S. Centers for Disease Control and Prevention (CDC) recommends meningococcal vaccines for both children and adults who are at increased risk for meningococcal disease.

The vaccine protect against the disease, which can lead to bacterial meningitis and other serious infections. Children ages 11 through 12 years should receive Meningococcal Vaccines followed by a booster dose at age 16 years. It is also recommended for all children aged 13 to 18 who did not receive a dose by age 11-12. Teens and young adults (aged 16 to 23 years old) may also get a MenB vaccine. A MenB vaccine protect people against infection by meningococcal group B bacteria, responsible for about 9 in every 10 meningococcal infections in children.

Meningococcal Vaccines Market are used to prevent diseases such as meningococcemia, meningitis, and septicemia caused due to Neisseria meningitidis. Several meningococcal serogroups have been identified, such as A, B, C, Y, and W-135. These serogroups are the most prominent ones causing meningococcal infection. Neisseria meningitidis can be classified into 12 serogroups based on its capsular polysaccharide; serogroups A, B, C, W, X, and Y are the primary causes of meningococcal disease worldwide.

Meningococcal ACWY vaccine protect against meningococcal disease caused by serogroups A, C, W, and Y. While meningococcal B vaccines protect against serogroup B meningococcal disease. Two types of Meningococcal Vaccines are available in the U.S., such as Meningococcal conjugate or MenACWY vaccines (MenQuadfi, Menveo, and Menactra) and MenB vaccines or Serogroup B meningococcal vaccine (Bexsero and Trumenba).

Comments

Post a Comment

Popular posts from this blog

Sarcopenia Treatment; Training and Physical Exercise Is Key to Counteract Sarcopenia

Image
Sarcopenia Treatment A primary Sarcopenia Treatment is exercise. Researchers have identified resistance training as the specific form of exercise that is most beneficial to individuals with sarcopenia. At present, resistance exercise, protein supplementation, and vitamin D have been established as the basic treatment of sarcopenia. Recent clinical trials on sarcopenia therapies such as physical exercise, nutraceutical, and pharmaceutical interventions have revealed that exercise is the only effective strategy shown to alleviate sarcopenia. Sarcopenia refers to a loss of muscle mass specifically related to aging. It's normal to lose some muscle mass as people age. Sarcopenia has been defined as an age-related, involuntary loss of skeletal muscle mass and strength. Although aging is the main cause of sarcopenia, some other factors contribute to the loss of muscle mass. Getting little or no physical activity on a regular basis puts people at an increased risk of developing sarcopenia
Read more

Bioresorbable Implants Can Also Help To Prevent Complications And Speed Up The Recovery Process

Image
Bioresorbable Implants Medical implants, either passive for structural support or for diagnosis and therapy with active electronics, are widely used in surgical applications. Although they have shown long-term biocompatibility, their removal imposes physical, biological and economical burdens on patients. To overcome this drawback, implantable devices exhibiting biodegradation in the body have been developed. These implants disappear inside the body after a certain time of use, and can be replaced with natural bone. The resorption of Bioresorbable Implants is driven by hydrolysis of the bonds linking their monomers. The amorphous portions of the polymer degrade first, while the crystalline regions remain intact and provide most of their mechanical strength. The monomers are then broken down into lactic and glycolic acids, which are converted to pyruvate and then processed through the citric acid cycle into water and carbon dioxide. The Bioresorbable Implants Market was valued at US$
Read more

Increasing Developments by Key Players Are Expected To Augment the Growth of the Global Digital Pathology Market

Image
 Digital Pathology Digital Pathology Market , by Product Type (Image Analysis Software, Scanner {Bright Field Scanner, Fluorescence Scanner}, Services {Installation & Integration, Maintenance Services, Consulting Services}), by Therapeutic Area (Oncology, Hematology, Autoimmune Disorder, Dermatology, and Others), by Technology (Immunohistochemistry, ISH & FISH, Immunofluorescence and others) End User (Pharmaceutical & Biotechnology Companies, Diagnostic Labs, Hospital Laboratories, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030. The global Digital Pathology Market is anticipated to reach an estimated value of US$ 884.4 million in 2023 and is projected to grow at a CAGR of 12.2% from 2023 to 2030. Market Overview: Digital pathology refers to the practice of digitizing glass slides containing tissue samples and analyzing them using digital imaging technology
Read more